Source: FUSE – March 7, 2018
Q BioMed, Inc., a New York-based biomedical acceleration and development company, recently announced an exclusive option agreement with Washington University in St. Louis to improve glaucoma diagnostic technology.
The agreement was executed through WashU’s Office of Technology Management (OTM) based on IP developed by Rajendra Apte, MD, PhD, Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences, and Jun Yoshino, MD, PhD, Assistant Professor of Medicine.
The Washington University School of Medicine researchers discovered a marker of cell damage in the eye that could be utilized to monitor glaucoma progression and treatment effectiveness. The biomarker growth differentiation factor 15 (GDF15) is part of the transforming growth factor (TGF-beta) superfamily and allows for earlier detection than conventional visual field tests, which cannot reliably measure whether a patient has a higher risk of quickly losing their vision.Read Full Article